AstraZeneca PLC's bid to remind observers that there is more to its oncology pipeline than MYSTIC has been spurred by two pieces of good news for its second-generation BTK inhibitor acalabrutinib: the product has been accepted for filing by the US FDA for use in second-line mantle cell lymphoma patients just a day after the agency awarded it a breakthrough therapy designation for the same indication.
While analysts were mildly disappointed that the filing, which the company previously billed as for an unspecified blood cancer, was...